Type 1 Diabetes: Autoimmune Etiology, Presentation & Lifelong Management

Type 1 diabetes (T1D) is a T-cell mediated autoimmune destruction of pancreatic β-cells, leading to absolute insulin deficiency.

Epidemiology & Risk

  • Incidence rising 3–4%/year; peak onset 10–14 yr, but any age (LADA in adults).
  • Genetic: HLA-DR3/DR4-DQ8 (40–50% heritability); >50 loci identified.
  • Environmental triggers: viral (enterovirus), early diet (cow's milk?), vitamin D, microbiome – not fully defined.

Classic Presentation (4 Ts)

  • Thirst (polydipsia)
  • Toilet (polyuria, nocturia, enuresis)
  • Tired (fatigue, weight loss despite hunger)
  • Thinner (weight loss)

DKA at diagnosis: 20–40% (higher in young children). Medical emergency.

Diagnosis

  • Hyperglycemia + ketonemia/ketonuria + autoantibodies (GAD65, IA-2, ZnT8, IAA, ICA).
  • C-peptide low/undetectable (confirms insulin deficiency).

Management

  • Insulin replacement: Basal-bolus (MDI) or insulin pump (CSII). Analogues (rapid: lispro, aspart, glulisine; long: glargine U100/U300, degludec).
  • Glucose monitoring: CGM (real-time) standard of care; improves HbA1c, reduces hypoglycemia.
  • Carbohydrate counting & insulin:carb ratios.
  • Education: Sick-day rules, hypoglycemia treatment (15-15 rule), glucagon (nasal/injectable).
  • Screening: Thyroid (Hashimoto's 15–30%), celiac, lipids, microalbumin, retinopathy (after 5 yr/10 yr age).

Emerging Therapies

  • Teplizumab (anti-CD3) – delays onset in stage 2 (high-risk).
  • Beta-cell replacement (islet transplant, stem-cell derived – Vertex VX-880).
  • Artificial pancreas (closed-loop systems: Tandem Control-IQ, Medtronic 780G, Omnipod 5).

With modern tech and support, people with T1D live full lives. Multidisciplinary team essential.

Diabetes - Related Articles